Canopy Growth's GAAP loss for fiscal year 2022 was C$0.32 billion, down 5.22 times from C$1.671 billion the previous year. Revenue declined 4.1% to C$582.218 million from C$607.198 million a year earlier.

Canopy Growth's GAAP loss in Q3 2022 fiscal year was C$115.496 million, down 7.1 times from C$829.251 million in the prior year. Revenue decreased 8.8% to C$155.024 million from C$169.907 million a year earlier.

Canopy Growth sells Cannabinoid Compound's cannabinoid drug business to Dermapharm Holding. Canopy Growth will receive €80 million and another €42.6 million if Cannabinoid Compound reaches certain development milestones. The deal is scheduled to close by the end of January 2022.

Canopy Growth's GAAP loss for Q2 FY 2022 was C$16.331 million, down 5.9 times from C$96.552 million in the prior year. Revenue decreased 3.4% to C$145.648 million from C$150.828 million a year earlier.